%D9%88%D8%B1%D9%85_%D9%86%D8%AE%D8%A7%D8%B9%D9%8A_%D9%85%D8%AA%D8%B9%D8%AF%D8%AF%E0%A6%AE%E0%A6%9C%E0%A7%8D%E0%A6%9C%E0%A6%BE%E0%A6%95%E0%A7%8B%E0%A6%B7%E0%A6%BE%E0%A6%B0%E0%A7%8D%E0%A6%AC%E0%A7%81%E0%A6%A6Mieloma_m%C3%BAltipleMultiple_myelomaMnoho%C4%8Detn%C3%BD_myelomMyelomatoseMultiples_Myelom%CE%A0%CE%BF%CE%BB%CE%BB%CE%B1%CF%80%CE%BB%CE%BF%CF%8D%CE%BD_%CE%BC%CF%85%CE%AD%CE%BB%CF%89%CE%BC%CE%B1Multiple_myelomaMieloma_m%C3%BAltipleMieloma%D9%85%D9%88%D9%84%D8%AA%DB%8C%D9%BE%D9%84_%D9%85%DB%8C%D9%84%D9%88%D9%85%D8%A7MyeloomaMy%C3%A9lomeMial%C3%B3maMieloma_m%C3%BAltiple%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%9E%D7%94_%D7%A0%D7%A4%D7%95%D7%A6%D7%94%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A5%80%E0%A4%AA%E0%A4%B2_%E0%A4%AE%E0%A4%BE%E0%A4%87%E0%A4%B2%E0%A5%8B%E0%A4%AE%E0%A4%BEMiel%C3%B3ma_multiplex%D4%B2%D5%A1%D5%A6%D5%B4%D5%A1%D5%AF%D5%AB_%D5%B4%D5%AB%D5%A5%D5%AC%D5%B8%D5%B4%D5%A1MyelomaSel_mielomaMerg%C3%A6xliMieloma_multiplo%E5%A4%9A%E7%99%BA%E6%80%A7%E9%AA%A8%E9%AB%84%E8%85%AB%D0%9C%D0%B8%D0%B5%D0%BB%D0%BE%D0%BC%D0%B0%EB%8B%A4%EB%B0%9C%EC%84%B1_%EA%B3%A8%EC%88%98%EC%A2%85%D0%9C%D0%B8%D0%B5%D0%BB%D0%BE%D0%BC%D0%B0MyelomaMieloma%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A4%BF%E0%A4%AA%E0%A4%B2_%E0%A4%AE%E0%A4%BE%E0%A4%87%E0%A4%B2%E0%A5%8B%E0%A4%AE%E0%A4%BE%E0%A4%AE%E0%A4%B2%E0%A5%8D%E0%A4%9F%E0%A4%BF%E0%A4%AA%E0%A4%B2_%E0%A4%AE%E0%A4%BE%E0%A4%AF%E0%A4%B2%E0%A5%8B%E0%A4%AE%E0%A4%BEMultipel_myeloomBenmargskreft%E0%AC%AE%E0%AC%B2%E0%AD%8D%E0%AC%9F%E0%AC%BF%E0%AC%AA%E0%AD%8D%E0%AC%B2_%E0%AC%AE%E0%AC%BE%E0%AD%9F%E0%AD%87%E0%AC%B2%E0%AD%8B%E0%AC%AE%E0%AC%BE%E0%A8%AC%E0%A8%B9%E0%A9%81-%E0%A8%AE%E0%A8%BE%E0%A8%87%E0%A8%B2%E0%A8%93%E0%A8%B2%E0%A9%8B%E0%A8%AE%E0%A8%BESzpiczak_mnogi%D9%85%D9%84%D9%BC%D9%8A%D9%BE%D9%84_%D9%85%D9%8A%D9%88%D9%84%D9%88%D9%85%D8%A7Mieloma_m%C3%BAltiplo%D0%9C%D0%B8%D0%B5%D0%BB%D0%BE%D0%BC%D0%BD%D0%B0%D1%8F_%D0%B1%D0%BE%D0%BB%D0%B5%D0%B7%D0%BD%D1%8C
about
Kjell GrandhagenAlan Mackay-SimTom LongBone Marrow Transplant Studies for Safe and Effective Treatment of LeukemiaA Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyA Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaSVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyTotal Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaAutologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaEvaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaMLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaPhase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceFollow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy StudiesAgriculture Health StudyPsychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family CaregiversUARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionCytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell TransplantDaratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantPneumococcal Vaccination of Multiple Myeloma Patients on Novel AgentsSafety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma PatientsTrial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Collection of Specimens and Clinical Data to Create A Bio-repository for Multiple MyelomaTherapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant RecipientsA Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationA Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesAn Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsDexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple MyelomaPhase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMT Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaPomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansPropylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationStudy of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesComparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple MyelomaVorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)The Molecular Characterization of Multiple Myeloma at RelapseA Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
P1050
Buddy CageMaria EstelaAngela CoughlanHulda Regehr ClarkRalph GinzburgHachirō KagaAkira ArimuraAkihiko TakaderaIra BerlinTimothy John ByfordHayden RorkeRichard BellJackie HudsonMax WalkerFernando ClavijoM. O. H. FarookJames W. HustonTerry ZahnMichael A. SheehanMel GoldsteinDavide Lufrano ChavesKjell GrandhagenCynthia Eagle RussettJulius HobsonFrank DelfinoDouglas BirksJudith MeuliRalph D. WinterRichard B. BrewerPeter A. RonaMichael ThomasI. A. L. DiamondJack RosenthalJean-Pierre SchmitzAlastair SmithJerome CooperJohn Blake, Jr.Arnold M. SilverAlan TurneyJim Bartels
P509
description
A myeloid neoplasm that is located in the plasma cells in bone marrow.
@en
Daganatos betegség
@hu
Krankheit, Häufung von Plasmazelltumoren
@de
cancro dos plasmócitos, um tip ...... el pela produção de anticorpos
@pt
diagnose
@da
kreftsykdom
@nb
malign tumörsjukdom i benmärgen
@sv
myolome canser
@fr
neoplasia sostenuta dalla prol ...... funzione di produrre anticorpi
@it
nádorové onemocnění
@cs
name
Diseminirani plazmacitom
@sl
Mergæxli
@is
Mialóma iolrach
@ga
Mieloma múltiple
@gl
Mieloma
@eu
Mieloma
@lt
Mielóma multiplex
@hu
Mnohočetný myelom
@cs
Multiple myeloma
@ckb
Multiple myeloma
@ko
type
label
Diseminirani plazmacitom
@sl
Mergæxli
@is
Mialóma iolrach
@ga
Mieloma múltiple
@gl
Mieloma
@eu
Mieloma
@lt
Mielóma multiplex
@hu
Mnohočetný myelom
@cs
Multiple myeloma
@ckb
Multiple myeloma
@ko
altLabel
Bence-Jones Plasmozytom
@de
Bence-Jones-Plasmozytom
@de
Cancer osseux
@fr
Kahler hastalığı
@tr
Kahler-Krankheit
@de
Kahlerova nemoc
@cs
Kahlers sjukdom
@nn
Knochenmarkkrebs
@de
Leichtkettenerkrankung
@de
M. Kahler
@nl
prefLabel
Diseminirani plazmacitom
@sl
Mergæxli
@is
Mialóma iolrach
@ga
Mieloma múltiple
@gl
Mieloma
@eu
Mieloma
@lt
Mielóma multiplex
@hu
Mnohočetný myelom
@cs
Multiple myeloma
@ckb
Multiple myeloma
@ko